Jessica M van der Bol Theo J Visser Walter J Loos Floris A de Jong Erik A C Wiemer Maarten O van Aken Andre S Planting Jan H Schellens Jaap Verweij Ron H J Mathijssen
10.1007/s00280-010-1414-x
Cancer Chemother Pharmacol
2011 Jan;67(1):231-6.
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/20680278/
Antineoplastic Agents, Phytogenic / pharmacokinetics Antithyroid Agents / pharmacology Camptothecin / analogs & derivatives Methimazole / pharmacology
Antineoplastic Agents, Phytogenic / pharmacokinetics Antithyroid Agents / pharmacology Camptothecin / analogs & derivatives Methimazole / pharmacology Case Reports Antineoplastic Agents, Phytogenic / adverse effects Antineoplastic Agents, Phytogenic / therapeutic use Camptothecin / adverse effects Camptothecin / pharmacokinetics Camptothecin / therapeutic use Colorectal Neoplasms / complications Colorectal Neoplasms / drug therapy Drug Interactions Glucuronides / metabolism Glucuronosyltransferase / drug effects Glucuronosyltransferase / metabolism Graves Disease / complications Graves Disease / drug therapy Humans Irinotecan Male Middle Aged Antineoplastic Agents, Phytogenic Antithyroid Agents Glucuronides Methimazole Irinotecan UGT1A1 enzyme Glucuronosyltransferase Camptothecin
PMC3016232
20680278
Effects of methimazole on the elimination of irinotecan
2011